-
EP2243776
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2243776
| EP2243776 - Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 11.11.2011 Database last updated on 09.07.2024 | Most recent event Tooltip | 11.11.2011 | Application deemed to be withdrawn | published on 14.12.2011 [2011/50] | Applicant(s) | For all designated states High Point Pharmaceuticals, LLC 4170 Mendenhall Oaks Parkway High Point, NC 27265 / US | [2010/43] | Inventor(s) | 01 /
Dörwald, Florencio Zaragoza Baretstrasse 2 3930 Visp / CH | [2010/43] | Representative(s) | Russell, Lindsey Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | [N/P] |
| Former [2010/43] | Russell, Lindsey Elkington and Fife LLP Thavies Inn House 3-4 Holborn Circus London EC1N 2HA / GB | Application number, filing date | 09169545.2 | 04.10.2002 | [2010/43] | Priority number, date | DK20010001506 | 12.10.2001 Original published format: DK 200101506 | [2010/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2243776 | Date: | 27.10.2010 | Language: | EN | [2010/43] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 01.09.2010 | Classification | IPC: | C07D401/02, C07D405/14, C07D409/14, C07D413/14, A61K31/4523, A61P3/00, A61P11/00 | [2010/43] | CPC: |
C07D401/06 (EP);
A61P1/00 (EP);
A61P1/04 (EP);
A61P1/08 (EP);
A61P1/14 (EP);
A61P1/16 (EP);
A61P11/00 (EP);
A61P11/02 (EP);
A61P11/06 (EP);
A61P13/08 (EP);
A61P19/02 (EP);
A61P25/00 (EP);
A61P25/02 (EP);
A61P25/06 (EP);
A61P25/08 (EP);
A61P25/20 (EP);
A61P25/24 (EP);
A61P25/26 (EP);
A61P25/28 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P35/00 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P5/00 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
A61P9/12 (EP);
C07D211/58 (EP);
C07D405/06 (EP);
C07D409/06 (EP);
C07D413/06 (EP)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR [2010/43] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | Substituierte Piperidine und ihre Verwendung zur Behandlung von Histamine H3 Rezeptor bedingten Erkrankungen | [2010/43] | English: | Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor | [2010/43] | French: | Piperidines substituées et leur utilisation dans le traitement de maladies liées au recepteur histaminique H3 | [2010/43] | Examination procedure | 28.04.2011 | Application deemed to be withdrawn, date of legal effect [2011/50] | 05.07.2011 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2011/50] | Parent application(s) Tooltip | EP02800545.2 / EP1444219 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20020800545) is 20.12.2006 | Fees paid | Renewal fee | 04.09.2009 | Renewal fee patent year 03 | 04.09.2009 | Renewal fee patent year 04 | 04.09.2009 | Renewal fee patent year 05 | 04.09.2009 | Renewal fee patent year 06 | 04.09.2009 | Renewal fee patent year 07 | 04.09.2009 | Renewal fee patent year 08 | 12.10.2010 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO0006254 (BIOPROJET SOC CIV [FR], et al) [X] 1-14 * see particularly compound 124, page 97; compound 176, page 107 and claims *; | [X]WO9420473 (YAMANOUCHI PHARMA CO LTD [JP], et al) [X] 1-14 * compound 25- B page 142 *; | [X]WO9743292 (KLINGE CO CHEM PHARM FAB [DE], et al) [X] 1-14 * see page 5 - page 6; table 1, example 37; table 2, examples 36 and 282 *; | [X]WO9743282 (KLINGE CO CHEM PHARM FAB [DE], et al) [X] 1-14 * see page 5 - page 6; table 1, examples 38,49 and 218; table 2, example 49 *; | [X]EP1008346 (SUNTORY LTD [JP]) [X] 1-14 * see page 5, line 8 - line 11; compound 165, page 64 *; | [X]EP0426180 (SQUIBB BRISTOL MYERS CO [US]) [X] 1-14 * see example 6, page 13 *; | [X]EP0091241 (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [X] 1-14 * see compound 8, page 22 *; | [X] - T. TERADA ET AL., "Antitumor agents. 3. Synthesis and biological activity of 4.beta.-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents", J. MED. CHEM., (199306), vol. 36, doi:10.1021/jm00064a002, pages 1689 - 1699, XP002596233 [X] 1-14 * compound 14b * DOI: http://dx.doi.org/10.1021/JM00064A002 | by applicant | US4943573 | WO0121206 | WO9948491 | WO9743282 | WO9743292 | WO8403089 | WO8401576 | WO8303410 | US3337551 | WO9942458 | EP0978512 | WO9717345 | EP0792290 | EP0214826 | EP0705275 | US5504188 | EP0368187 | WO9808871 | WO9726265 | WO9903861 | WO0037474 | WO9901423 | WO0039088 | WO0042026 | WO9741097 | WO9741119 | WO9741120 | WO0041121 | WO9845292 | WO9919313 | WO0050414 | WO0063191 | WO0063192 | WO0063193 | WO0023425 | WO0023415 | WO0023451 | WO0023445 | WO0023417 | WO0023416 | WO0063153 | WO0063196 | WO0063209 | WO0063190 | WO0063189 | - STARK, H., DRUGS FUT., (1996), vol. 21, pages 507 - 520 | - LEURS, R.; TIMMERMAN, H.; VOLLINGA, R. C., PROGRESS IN DRUG RESEARCH, (1995), vol. 45, pages 107 - 165 | - LOVENBERG, T.W. ET AL., MOLECULAR PHARMACOLOGY, (199906), vol. 55, pages 1101 - 1107 | - MORISSET ET AL., NATURE, (2000), vol. 408, pages 860 - 864 | - CHEMICAL ABSTRACTS, Database accession no. 46341 | - ARCH. PHARM., (1979), vol. 312, no. 8, pages 670 - 681 | - MEANWELL, N. A. ET AL., J. MED, CHEM., (1992), vol. 35, no. 14, pages 2688 - 2696 | - DRUGS DES. DISCOVERY, (1995), vol. 12, no. 3, pages 249 - 258 | - WEINSTOCK, L. T. ET AL., J. PHARM. SCI., (1981), vol. 70, no. 8, pages 956 - 959 | - STARK ET AL., DRUGS OF THE FUTURE, (1996), vol. 21, pages 507 - 520 | - TOZER; KALINDDJLAN, EXPERT OPINION ON THERAPEUTIC PATENTS, (2000), vol. 10, pages 1045 - 1055 | - WALCZYNSKI ET AL., ARCH. PHARM. PHARM. MED. CHEM., (1999), vol. 332, pages 389 - 398 | - LINNEY ET AL., J. MED. CHEM., (2000), vol. 43, pages 2362 - 2370 | - GANELLIN ET AL., ARCH. PHARM. PHARM. MED. CHEM., (1998), vol. 331, pages 395 - 404 | - WALCZYNSKI ET AL., LL FARMACO, (1999), vol. 54, pages 684 - 694 | - J. PHARM. SCI., J. PHARM. SCI., (1977), vol. 66, page 2 | - R.L. MCLEOD ET AL., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1998), vol. 287, pages 43 - 50 | - C.J. MACKINS; R. LEVI, EXPERT OPINION ON INVESTIGATIONAL DRUGS, (2000), vol. 9, pages 2537 - 2542 |